After adjustment for multiple testing with a false discovery rate of 10%, a significant GV enrichment in the glioma versus the control cohort was found for nine genes, i.e., one CPG (BRCA2) and eight novel genes not previously associated with glioma risk, with 26 different GVs considered pathogenic GVs (Fig. 1a, Supplementary Table 3 online resource). Here, BRCA2 is linked to central nervous system cancer.